SurveyMonkey Powered Online Survey

Question Title

* 1. Please select the extent to which you agree/disagree that the activity supported the achievement of each learning objective:

	Strongly Agree (5)	Agree (4)	No Opinion (3)	Disagree (2)	Strongly Disagree (1)
Describe the rationale and benefits of combining GLP-1 RA with basal insulin	Describe the rationale and benefits of combining GLP-1 RA with basal insulin Strongly Agree (5)	Describe the rationale and benefits of combining GLP-1 RA with basal insulin Agree (4)	Describe the rationale and benefits of combining GLP-1 RA with basal insulin No Opinion (3)	Describe the rationale and benefits of combining GLP-1 RA with basal insulin Disagree (2)	Describe the rationale and benefits of combining GLP-1 RA with basal insulin Strongly Disagree (1)
Outline the differences between short-acting and long-acting GLP-1 RAs	Outline the differences between short-acting and long-acting GLP-1 RAs Strongly Agree (5)	Outline the differences between short-acting and long-acting GLP-1 RAs Agree (4)	Outline the differences between short-acting and long-acting GLP-1 RAs No Opinion (3)	Outline the differences between short-acting and long-acting GLP-1 RAs Disagree (2)	Outline the differences between short-acting and long-acting GLP-1 RAs Strongly Disagree (1)
Discuss guideline recommendations for when and in whom to use combination GLP-1 RA and basal insulin	Discuss guideline recommendations for when and in whom to use combination GLP-1 RA and basal insulin Strongly Agree (5)	Discuss guideline recommendations for when and in whom to use combination GLP-1 RA and basal insulin Agree (4)	Discuss guideline recommendations for when and in whom to use combination GLP-1 RA and basal insulin No Opinion (3)	Discuss guideline recommendations for when and in whom to use combination GLP-1 RA and basal insulin Disagree (2)	Discuss guideline recommendations for when and in whom to use combination GLP-1 RA and basal insulin Strongly Disagree (1)
Summarize available data regarding safety and efficacy of combined, fixed ratio GLP-1 RA and basal insulin	Summarize available data regarding safety and efficacy of combined, fixed ratio GLP-1 RA and basal insulin Strongly Agree (5)	Summarize available data regarding safety and efficacy of combined, fixed ratio GLP-1 RA and basal insulin Agree (4)	Summarize available data regarding safety and efficacy of combined, fixed ratio GLP-1 RA and basal insulin No Opinion (3)	Summarize available data regarding safety and efficacy of combined, fixed ratio GLP-1 RA and basal insulin Disagree (2)	Summarize available data regarding safety and efficacy of combined, fixed ratio GLP-1 RA and basal insulin Strongly Disagree (1)

Question Title

* 2. Please rate the extent to which you agree/disagree that the activity achieved the following:

	Strongly Agree (5)	Agree (4)	No Opinion (3)	Disagree (2)	Strongly Disagree (1)
The faculty demonstrated expertise on the topic presented.	The faculty demonstrated expertise on the topic presented. Strongly Agree (5)	The faculty demonstrated expertise on the topic presented. Agree (4)	The faculty demonstrated expertise on the topic presented. No Opinion (3)	The faculty demonstrated expertise on the topic presented. Disagree (2)	The faculty demonstrated expertise on the topic presented. Strongly Disagree (1)
The faculty selected up-to-date information that was relevant to the topic	The faculty selected up-to-date information that was relevant to the topic Strongly Agree (5)	The faculty selected up-to-date information that was relevant to the topic Agree (4)	The faculty selected up-to-date information that was relevant to the topic No Opinion (3)	The faculty selected up-to-date information that was relevant to the topic Disagree (2)	The faculty selected up-to-date information that was relevant to the topic Strongly Disagree (1)
The educational material provided useful information for my practice.	The educational material provided useful information for my practice. Strongly Agree (5)	The educational material provided useful information for my practice. Agree (4)	The educational material provided useful information for my practice. No Opinion (3)	The educational material provided useful information for my practice. Disagree (2)	The educational material provided useful information for my practice. Strongly Disagree (1)
The activity enhanced my current knowledge base.	The activity enhanced my current knowledge base. Strongly Agree (5)	The activity enhanced my current knowledge base. Agree (4)	The activity enhanced my current knowledge base. No Opinion (3)	The activity enhanced my current knowledge base. Disagree (2)	The activity enhanced my current knowledge base. Strongly Disagree (1)
The activity enhanced my current competence	The activity enhanced my current competence Strongly Agree (5)	The activity enhanced my current competence Agree (4)	The activity enhanced my current competence No Opinion (3)	The activity enhanced my current competence Disagree (2)	The activity enhanced my current competence Strongly Disagree (1)
The opportunities provided to assess my own learning were appropriate (e.g. questions before, during, or after the activity).	The opportunities provided to assess my own learning were appropriate (e.g. questions before, during, or after the activity). Strongly Agree (5)	The opportunities provided to assess my own learning were appropriate (e.g. questions before, during, or after the activity). Agree (4)	The opportunities provided to assess my own learning were appropriate (e.g. questions before, during, or after the activity). No Opinion (3)	The opportunities provided to assess my own learning were appropriate (e.g. questions before, during, or after the activity). Disagree (2)	The opportunities provided to assess my own learning were appropriate (e.g. questions before, during, or after the activity). Strongly Disagree (1)

Question Title

* 3. Based upon your participation in this activity, do you intend to change your clinical practice behavior?

Yes

Question Title

* 4. How confident are you that you will be able to make your intended changes?

Very Confident

Somewhat Confident

Unsure

Not Very Confident

Question Title

* 5. Which of the following do you anticipate will be the primary barrier to implementing these changes? (Please check all that apply)

Formulary restrictions

Insurance/financial issues

Time constraints

Lack of multidisciplinary support

System constraints

Treatment related adverse events

Patient adherence/compliance

Lack of confidence in applying information to clinical practice

Other (please specify)

Question Title

* 6. Was the content of this activity fair, balanced, objective and free of commercial bias?

Yes

Question Title

* 7. Do you currently use combination therapy of a GLP-1 RA and basal insulin in your practice?

Yes

Question Title

* 8. Do you plan use this combination more often in appropriate patients?

Yes

Question Title

* 9. What other topics would you be interested in hearing about? (Please check all that apply)

Oral Diabetic Medications

Insulin

Osteoarthritis

Multiple Sclerosis (MS)

Anticoagulation

Chronic Obstructive Pulmonary Disease (COPD)

Depression

Hepatitis

Pain Management

Arthritis

Opioid Use

Other (please specify)

Question Title

* 10. Any additional comments you would like to express?

Question Title

* 11. If you plan to change your clinical practice behavior, what type of changes do you plan to implement? (Please check all that apply)

Assess glycemic control more frequently and intensify treatment if A1C target is not achieved

Assess the relative contribution of postprandial hyperglycemia to a patient's overall glycemic control when evaluating A1C

Evaluate postprandial glucose levels to check for residual hyperglycemia in patients with type 2 diabetes

Add bolus insulin (mealtime insulin) to treat postprandial glucose excursions in type 2 diabetes patients on basal insulin that are not meeting their A1C target

Add a GLP-1 receptor agonist to treat postprandial glucose excursions in type 2 diabetes patients on basal insulin that are not meeting their A1C target

Consider initiating combination therapy of GLP-1 receptor agonist + basal insulin earlier in the course of therapy for patients with type 2 diabetes

Other (please specify)